CP-223 Effectiveness and safety using eribulin in metastatic breast cancer

Background Eribulin is approved for use in pretreated metastatic breast cancer (MBC) patients after at least two chemotherapy regimens for advanced disease. Purpose To assess the effectiveness and safety of eribulin in MBC. Material and methods Retrospective observational study in patients treated with eribulin monotherapy from February 2014 to September 2015 in a tertiary hospital. Effectiveness was measured with OS and PFS. Safety was assessed by NCI-CTCAE criteria v.3.0. Data collected were: sex, age, immunohistochemistry, location and degree of metastasis, ECOG, prior lines of treatment, number of cycles of eribulin and adverse events. The information was obtained from Oncofarm program and digital Diraya history. Data analysis was performed using PASW Stadistic18 package. Results 19 women were studied, median age 55 years (38–73), ECOG 0–2, RH+ (68.4%) and HER2+ (15.78%) receptors. All patients had metastases IIIb-IV grade in different locations: liver (63.15%), bone (57.9%), lung (26.3%), brain (10.52%) and nodal (10.52%). They previously received a median of 6 lines of treatment (3–9): anthracyclines (89.47%), capecitabine (84.2%), taxanes (78.9%) and vinorelbine (63%). Eribulin dose was 1.23 mg/m² on days 1 and 8, 21 day cycles intravenously. The average number of cycles administered was 4.75. Median OS was 2.5 months obtained with 95% CI (0.5 to 8.6) and PFS was 5.2 months with 95% CI (3.4 to 7). Eight patients continue on treatment today. Adverse effects observed were: asthenia grade II (n = 2), diarrhoea grade I (n = 1), constipation grade I (n = 1) and febrile neutropenia grade IV (n = 1). Conclusion Our results agree with those already published; a similar OS and a higher PFS than obtained in the pivotal trial. Also, minimal toxicity was observed. We conclude that eribulin monotherapy is an effective and safe drug for MBC used as the 5th or 6th line of treatment. References and/or Acknowledgements European Medicines Agency. Halaven EPAR Product Information. EMA/H/C/002213/2011 No conflict of interest.